Research Center for Functional Genomics, Biomedicine and Translational Medicine, Iuliu-Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.
Department of Psychology, Babes-Bolyai University, Cluj-Napoca, Romania.
Cancer Metastasis Rev. 2018 Mar;37(1):17-32. doi: 10.1007/s10555-017-9714-9.
The involvement of microRNAs in malignant transformation and cancer progression was previously grounded. The observations made by multiple published studies led to the conclusion that some of these small sequences could be eventually used as biomarkers for diagnosis/prognosis. This meta-analysis investigated whether microRNA-181 family members could predict the outcome of patients carrying different types of cancer. We searched the PubMed and Embase databases for studies evaluating the expression levels of miR-181a/b/c/d in patients with cancer, selecting the publications that assessed the relation between low and high levels of one of these four microRNAs and patients' outcome. Hazard ratios (HRs) or risk ratios (RRs) were extracted from the studies, and random-effect model was performed to investigate the role of miR-181 in the outcome of these patients. The meta-analysis comprised 26 studies including 2653 cancer patients from 6 countries. The results showed significant association between the expression of miR-181 family members and colorectal cancer. Considering the heterogeneity of the pathologies, the analysis, including all types of cancer and the expression of all the miR-181 family members together, showed no association with distinct outcome (HR = 1.099, p = 0.435). When the analysis was performed on each microRNA separately, the expression of miR-181c was significantly associated with the outcome of patients with cancer (HR = 2.356, p = 0.011) and miR-181a expression levels significantly correlated with survival in patients with non-small-cell lung cancer (HR = 0.177, p < 0.05). This meta-analysis revealed evidence regarding the involvement of miR-181 family members in the outcome of patients with some types of cancer, according to their expression level.
微 RNA 参与恶性转化和癌症进展早已得到证实。多项已发表研究的观察结果得出结论，其中一些小序列最终可能被用作诊断/预后的生物标志物。本荟萃分析研究了微 RNA-181 家族成员是否可以预测不同类型癌症患者的预后。我们在 PubMed 和 Embase 数据库中搜索了评估癌症患者 miR-181a/b/c/d 表达水平的研究，选择了评估这四个微 RNA 中任何一个的高低水平与患者结局之间关系的出版物。从研究中提取危险比（HRs）或风险比（RRs），并采用随机效应模型研究 miR-181 在这些患者结局中的作用。荟萃分析包括来自 6 个国家的 2653 名癌症患者的 26 项研究。结果表明 miR-181 家族成员的表达与结直肠癌显著相关。考虑到病理的异质性，包括所有类型的癌症和 miR-181 家族所有成员的表达在内的分析与不同的结局无关（HR=1.099，p=0.435）。当分别对每个微 RNA 进行分析时，miR-181c 的表达与癌症患者的结局显著相关（HR=2.356，p=0.011），miR-181a 的表达水平与非小细胞肺癌患者的生存显著相关（HR=0.177，p<0.05）。这项荟萃分析揭示了微 RNA-181 家族成员根据其表达水平参与某些类型癌症患者结局的证据。
